CoChat
Sign Up
Cited by 42Cervical Cancer and HPV ResearchReproductive tract infections researchWomen's cancer prevention and management

HPV genotype distribution in Brazilian women with and without cervical lesions: correlation to cytological data

Open access
Martins, Toni Ricardo, Mendes de Oliveira, Cristina, Rosa, Luciana Reis, de Campos Centrone, Cristiane, Rodrigues, Célia Luiza Regina, Villa, Luisa Lina, Levi, José Eduardo·2016·Virology Journal
DOI 10.1186/s12985-016-0594-3PMC PMC4982268
Open this paper in CoChat — free accountOpen PDF

Abstract

BACKGROUND: Human Papillomavirus (HPV) genotype distribution varies according to the method of assessment and population groups. This study analyzed type-specific HPV infections among women ranging from 14-95 years old, displaying normal and abnormal cytology, from São Paulo and Barretos cities, Brazil. METHODS: Women found positive for High Risk-HPVs DNA by either the Hybrid Capture 2 (HC2) or Cobas HPV Test (n = 431) plus a random sample of 223 negative by both assays and 11 samples with indeterminate results, totalizing 665 samples, were submitted to HPV detection by the PapilloCheck test. Cytological distribution included 499 women with a cytological result of Negative for Intraepithelial Lesion or Malignancy and 166 with some abnormality as follows: 54 Atypical Squamous Cells of Undetermined Significance; 66 Low-Grade Squamous Intraepithelial Lesion; 43 High-Grade Squamous Intraepithelial Lesion and 3 (0.5 %) Invasive Cervical Cancer. RESULTS: From the 323 samples (48.6 %) that had detectable HPV-DNA by the PapilloCheck assay, 31 were HPV negative by the cobas HPV and HC2 assays. Out of these 31 samples, 14 were associated with HR-HPVs types while the remaining 17 harbored exclusively low-risk HPVs. In contrast, 49 samples positive by cobas HPV and HC 2 methods tested negative by the PapilloCheck assay (19.8 %). Overall, the most frequent HR-HPV type was HPV 16 (23.2 %), followed by 56 (21.0 %), 52 (8.7 %) and 31 (7.7 %) and the most frequent LR-HPV type was HPV 42 (12.1 %) followed by 6 (6.2 %). Among the HR-HPV types, HPV 56 and 16 were the most frequent types in NILM, found in 19.1 and 17.7 % of the patients respectively while in HSIL and ICC cases, HPV 16 was the predominant type, detected in 37.2 and 66.7 % of these samples. CONCLUSIONS: In the population studied, HPV 16 and 56 were the most frequently detected HR-HPV types. HPV 56 was found mainly in LSIL and NILM suggesting a low oncogenic potential. HPV 16 continues to be the most prevalent type in high-grade lesions whereas HPV 18 was found in a low frequency both in NILM and abnormal smears. Surveillance of HPV infections by molecular methods is an important tool for the development and improvement of prevention strategies.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12985-016-0594-3

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Sexual activity is higher in younger women.

    “Since sexual activity is higher in younger women, multiple genotype infection is higher at this age [30–32].”

    From HPV Genotypes distribution in Indian women with and without cervical carcinoma: Implication for HPV vaccination program in Odisha, Eastern India (2017) · cites this paper as [32]

    The Discussion reports that multiple HPV infections were more frequent in women under 31, but only suggests that this may be associated with more intense sexual activity in younger women. It does not establish the citing sentence’s categorical claim about sexual activity. Page numbers are not provided in our copy. (LLM, conf=0.87)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 66

  1. [1]Kocjan BJ Bzhalava D Forslund O Dillner J Poljak M Molecular methods for identification and characterization of novel papillomaviruses Clin Microbiol Infect 2015 21 9 808 16 10.1016/j.cmi.2015.05.011 26003284 · DOI
  2. [2]Munoz N Bosch FX de Sanjose S Herrero R Castellsague X Shah KV Epidemiologic classification of human papillomavirus types associated with cervical cancer N Engl J Med 2003 348 6 518 27 10.1056/NEJMoa021641 12571259 · DOI · Paper page
  3. [3]Piana A Sotgiu G Castiglia P Pischedda S Cocuzza C Capobianco G Prevalence and type distribution of human papillomavirus infection in women from North Sardinia, Italy BMC Public Health 2011 11 785 10.1186/1471-2458-11-785 21989375 PMC3208589 · DOI
  4. [4]de Oliveira CM Aguiar LS Genta ML Alves VA Levi JE HPV-11 associated metastatic cervical cancer Gynecol Oncol Case Rep 2011 2 1 18 9 10.1016/j.gynor.2011.11.004 24371604 PMC3860686 · DOI
  5. [5]Bouvard V Baan R Straif K Grosse Y Secretan B El Ghissassi F A review of human carcinogens--Part B: biological agents Lancet Oncol 2009 10 4 321 2 10.1016/S1470-2045(09)70096-8 19350698 · DOI · Paper page
  6. [6]de Sanjose S Quint WG Alemany L Geraets DT Klaustermeier JE Lloveras B Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study Lancet Oncol 2010 11 11 1048 56 10.1016/S1470-2045(10)70230-8 20952254 · DOI · Paper page
  7. [7]de Sanjose S Diaz M Castellsague X Clifford G Bruni L Munoz N Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis Lancet Infect Dis 2007 7 7 453 9 10.1016/S1473-3099(07)70158-5 17597569 · DOI · Paper page
  8. [8]Fernandes JV Meissner Rde V de Carvalho MG Fernandes TA de Azevedo PR Villa LL Prevalence of HPV infection by cervical cytologic status in Brazil Int J Gynaecol Obstet 2009 105 1 21 4 10.1016/j.ijgo.2008.12.004 19150057 · DOI
  9. [9]Matsumoto K Oki A Furuta R Maeda H Yasugi T Takatsuka N Predicting the progression of cervical precursor lesions by human papillomavirus genotyping: a prospective cohort study Int J Cancer 2011 128 12 2898 910 10.1002/ijc.25630 20734388 · DOI
  10. [10]Powell NG Hibbitts SJ Boyde AM Newcombe RG Tristram AJ Fiander AN The risk of cervical cancer associated with specific types of human papillomavirus: a case–control study in a UK population Int J Cancer 2011 128 7 1676 82 10.1002/ijc.25485 20503274 · DOI
  11. [13]Otero-Motta AP Ordonez JL Gonzalez-Celador R Rivas B Macias Mdel C Bullon A Prevalence of human papillomavirus genotypes in cytologic abnormalities from unvaccinated women living in north-western Spain APMIS 2011 119 3 204 15 10.1111/j.1600-0463.2010.02711.x 21284738 · DOI
  12. [14]Levi JE Longatto-filho A Eluf-neto J Rodrigues CL Oliveira CM Carloni AC Lorenzi AT Tacla M Fregnani JHTG Ab’saber AM Scapulatempo C Villa LL Evaluation of HPV molecular tests in primary screening for cervical cancer in Brazil Open J Obstet Gynecol 2014 4 470 8 10.4236/ojog.2014.48068 · DOI
  13. [15]Bruno A Serravalle K Travassos AG Lima BGC Distribuição dos Genótipos de papillomavírus humano em mulheres do estado da Bahia, Brasil Rev Bras Ginecol Obstet 2014 36 9 416 22 10.1590/SO100-720320140004995 25272363 · DOI
  14. [16]Herrero R Castle PE Schiffman M Bratti MC Hildesheim A Morales J Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica J Infect Dis 2005 191 11 1796 807 10.1086/428850 15871111 · DOI · Paper page
  15. [17]Kjaer SK Breugelmans G Munk C Junge J Watson M Iftner T Population-based prevalence, type- and age-specific distribution of HPV in women before introduction of an HPV-vaccination program in Denmark Int J Cancer 2008 123 8 1864 70 10.1002/ijc.23712 18661520 · DOI
  16. [18]Li N Franceschi S Howell-Jones R Snijders PJ Clifford GM Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication Int J Cancer 2011 128 4 927 35 10.1002/ijc.25396 20473886 · DOI
  17. [19]Bruni L Diaz M Castellsague X Ferrer E Bosch FX de Sanjose S Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings J Infect Dis 2010 202 12 1789 99 10.1086/657321 21067372 · DOI
  18. [20]Noronha V Mello W Villa L Brito A Macedo R Bisi F Human papillomavirus associated with uterine cervix lesions Rev Soc Bras Med Trop 1999 32 3 235 40 10.1590/S0037-86821999000300003 10380561 · DOI
  19. [21]Eluf-Neto J Booth M Munoz N Bosch FX Meijer CJ Walboomers JM Human papillomavirus and invasive cervical cancer in Brazil Br J Cancer 1994 69 1 114 9 10.1038/bjc.1994.18 8286192 PMC1968795 · DOI
  20. [22]Oliveira-Silva M Lordello CX Zardo LM Bonvicino CR Moreira MA Human Papillomavirus in Brazilian women with and without cervical lesions Virol J 2011 8 4 10.1186/1743-422X-8-4 21208414 PMC3024957 · DOI
  21. [23]Baldez da Silva MF Chagas BS Guimaraes V Katz LM Felix PM Miranda PM HPV31 and HPV33 incidence in cervical samples from women in Recife, Brazil Genet Mol Res 2009 8 4 1437 43 10.4238/vol8-4gmr677 20013657 · DOI
  22. [24]Rabelo-Santos SH Zeferino L Villa LL Sobrinho JP Amaral RG Magalhaes AV Human papillomavirus prevalence among women with cervical intraepithelial neoplasia III and invasive cervical cancer from Goiania, Brazil Mem Inst Oswaldo Cruz 2003 98 2 181 4 10.1590/S0074-02762003000200003 12764431 · DOI
  23. [25]Tozetti IA Scapulatempo IDL Kawski VL Ferreira AW Levi JE Multiple types of human papillomavirus in cervical samples in women in Campo Grande, MS, Brazil BJID 2006 10 5 309 10 17293916
  24. [26]Castilho JL Levi JE Luz PM Cambou MC Vanni T de Andrade A A cross-sectional study of high-risk human papillomavirus clustering and cervical outcomes in HIV-infected women in Rio de Janeiro, Brazil BMC Cancer 2015 15 478 10.1186/s12885-015-1486-4 26100400 PMC4477502 · DOI
  25. [27]Cuzick J Screening for cancer: future potential Eur J Cancer 1999 35 5 685 92 10.1016/S0959-8049(99)00070-2 10505025 · DOI
  26. [28]Brismar-Wendel S Froberg M Hjerpe A Andersson S Johansson B Age-specific prevalence of HPV genotypes in cervical cytology samples with equivocal or low-grade lesions Br J Cancer 2009 101 3 511 7 10.1038/sj.bjc.6605165 19623178 PMC2720239 · DOI
  27. [29]Arbyn M Verdoodt F Snijders PJ Verhoef VM Suonio E Dillner L Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis Lancet Oncol 2014 15 2 172 83 10.1016/S1470-2045(13)70570-9 24433684 · DOI · Paper page
  28. [30]Mayrand MH Duarte-Franco E Rodrigues I Walter SD Hanley J Ferenczy A Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer N Engl J Med 2007 357 16 1579 88 10.1056/NEJMoa071430 17942871 · DOI
  29. [31]Sankaranarayanan R Nene BM Shastri SS Jayant K Muwonge R Budukh AM HPV screening for cervical cancer in rural India N Engl J Med 2009 360 14 1385 94 10.1056/NEJMoa0808516 19339719 · DOI · Paper page
  30. [32]Ronco G Giorgi-Rossi P Carozzi F Confortini M Dalla Palma P Del Mistro A Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial Lancet Oncol 2010 11 3 249 57 10.1016/S1470-2045(09)70360-2 20089449 · DOI
  31. [33]Sandri MT Riggio D Salvatici M Passerini R Zorzino L Boveri S Typing of human papillomavirus in women with cervical lesions: prevalence and distribution of different genotypes J Med Virol 2009 81 2 271 7 10.1002/jmv.21382 19107962 · DOI
  32. [34]Vidal AC Murphy SK Hernandez BY Vasquez B Bartlett JA Oneko O Distribution of HPV genotypes in cervical intraepithelial lesions and cervical cancer in Tanzanian women Infect Agent Cancer 2011 6 1 20 10.1186/1750-9378-6-20 22081870 PMC3262746 · DOI
  33. [37]Nayar R Wilbur DC The Pap test and Bethesda 2014 Cancer Cytopathol 2015 123 5 271 81 10.1002/cncy.21521 25931431 · DOI · Paper page
  34. [38]de Villiers EM Fauquet C Broker TR Bernard HU zur Hausen H Classification of papillomaviruses Virology 2004 324 1 17 27 10.1016/j.virol.2004.03.033 15183049 · DOI
  35. [39]Capra G Giovannelli L Bellavia C Migliore MC Caleca MP Perino A HPV genotype prevalence in cytologically abnormal cervical samples from women living in south Italy Virus Res 2008 133 2 195 200 10.1016/j.virusres.2007.12.020 18282628 · DOI
  36. [40]Bosch FX Lorincz A Munoz N Meijer CJ Shah KV The causal relation between human papillomavirus and cervical cancer J Clin Pathol 2002 55 4 244 65 10.1136/jcp.55.4.244 11919208 PMC1769629 · DOI
  37. [41]Trottier H Franco EL The epidemiology of genital human papillomavirus infection Vaccine 2006 24 Suppl 1 S1 15 16406226
  38. [42]Bosch FX Burchell AN Schiffman M Giuliano AR de Sanjose S Bruni L Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia Vaccine 2008 26 Suppl 10 K1 16 10.1016/j.vaccine.2008.05.064 18847553 · DOI
  39. [43]de Ona M Alvarez-Arguelles ME Torrents M Villa L Rodriguez-Feijoo A Palacio A Prevalence, evolution, and features of infection with human papillomavirus: a 15-year longitudinal study of routine screening of a women population in the north of Spain J Med Virol 2010 82 4 597 604 10.1002/jmv.21697 20166173 · DOI
  40. [44]Delgado D Marin JM de Diego J Guerra S Gonzalez B Barrios JL Human papillomavirus (HPV) genotype distribution in women with abnormal cervical cytology in the Basque Country, Spain Enferm Infecc Microbiol Clin 2012 30 5 230 5 10.1016/j.eimc.2011.10.021 22206950 · DOI
  41. [45]Martin P Kilany L Garcia D Lopez-Garcia AM Martin-Azana MJ Abraira V Human papillomavirus genotype distribution in Madrid and correlation with cytological data BMC Infect Dis 2011 11 316 10.1186/1471-2334-11-316 22081930 PMC3231944 · DOI
  42. [46]Schopp B Holz B Zago M Stubenrauch F Petry KU Kjaer SK Evaluation of the performance of the novel PapilloCheck HPV genotyping test by comparison with two other genotyping systems and the HC2 test J Med Virol 2010 82 4 605 15 10.1002/jmv.21719 20166179 · DOI
  43. [47]Ciapponi A Bardach A Glujovsky D Gibbons L Picconi MA Type-specific HPV prevalence in cervical cancer and high-grade lesions in Latin America and the Caribbean: systematic review and meta-analysis PLoS One 2011 6 10 e25493 10.1371/journal.pone.0025493 21991313 PMC3186785 · DOI
  44. [48]de Oliveira CM Fregnani JH Carvalho JP Longatto-Filho A Levi JE Human papillomavirus genotypes distribution in 175 invasive cervical cancer cases from Brazil BMC Cancer 2013 13 357 10.1186/1471-2407-13-357 23883423 PMC3725167 · DOI
  45. [49]Argyri E Papaspyridakos S Tsimplaki E Michala L Myriokefalitaki E Papassideri I A cross sectional study of HPV type prevalence according to age and cytology BMC Infect Dis 2013 13 53 10.1186/1471-2334-13-53 23363541 PMC3575232 · DOI
  46. [50]Vieira L Almeida A The cytology and DNA detection by the PapilloCheck((R)) test in the diagnosis of human papillomavirus infection Eur J Microbiol Immunol (Bp) 2013 3 1 61 7 10.1556/EuJMI.3.2013.1.9 24265920 PMC3832079 · DOI
  47. [51]Stoler MH Castle PE Solomon D Schiffman M The expanded use of HPV testing in gynecologic practice per ASCCP-guided management requires the use of well-validated assays Am J Clin Pathol 2007 127 3 335 7 10.1309/RNF3C01JKADQCLKP 17276947 · DOI
  48. [52]Solomon D Chapter 14: role of triage testing in cervical cancer screening J Natl Cancer Inst Monogr 2003 31 97 101 10.1093/oxfordjournals.jncimonographs.a003489 12807952 · DOI
  49. [53]Schiffman M Wentzensen N Wacholder S Kinney W Gage JC Castle PE Human papillomavirus testing in the prevention of cervical cancer J Natl Cancer Inst 2011 103 5 368 83 10.1093/jnci/djq562 21282563 PMC3046952 · DOI
  50. [54]Cuzick J Mayrand MH Ronco G Snijders P Wardle J Chapter 10: new dimensions in cervical cancer screening Vaccine 2006 24 Suppl 3 S3/90 7 16950022
  51. [55]Ferreccio C Barriga MI Lagos M Ibanez C Poggi H Gonzalez F Screening trial of human papillomavirus for early detection of cervical cancer in Santiago Chile Int J Cancer 2013 132 4 916 23 10.1002/ijc.27662 22684726 · DOI
  52. [56]Castellsague X Natural history and epidemiology of HPV infection and cervical cancer Gynecol Oncol 2008 110 3 Suppl 2 S4 7 10.1016/j.ygyno.2008.07.045 18760711 · DOI
  53. [57]Castle PE Solomon D Wheeler CM Gravitt PE Wacholder S Schiffman M Human papillomavirus genotype specificity of hybrid capture 2 J Clin Microbiol 2008 46 8 2595 604 10.1128/JCM.00824-08 18579716 PMC2519476 · DOI
  54. [58]Guo M Hu L Baliga M He Z Hughson MD The predictive value of p16(INK4a) and hybrid capture 2 human papillomavirus testing for high-grade cervical intraepithelial neoplasia Am J Clin Pathol 2004 122 6 894 901 10.1309/0DGGQBDQAMJCJBXB 15539381 · DOI
  55. [59]Herrington CS Do HPV-negative cervical carcinomas exist?--revisited J Pathol 1999 189 1 1 3 10.1002/(SICI)1096-9896(199909)189:1<1::AID-PATH432>3.0.CO;2-P 10451480 · DOI
  56. [60]Peevor R Bowden S Jones J Fiander AN Hibbitts S Human Papillomavirus negative but dyskaryotic cervical cytology: re-analysis of molecular testing J Clin Virol 2009 44 4 322 4 10.1016/j.jcv.2009.01.015 19264544 · DOI
  57. [61]Gray SH Walzer TB New strategies for cervical cancer screening in adolescents Curr Opin Pediatr 2004 16 4 344 9 10.1097/01.mop.0000133078.40007.2b 15273491 · DOI
  58. [62]Mejlhede N Bonde J Fomsgaard A High frequency of multiple HPV types in cervical specimens from Danish women APMIS 2009 117 2 108 14 10.1111/j.1600-0463.2008.00019.x 19239432 · DOI
  59. [63]Gonzalez-Bosquet E Esteva C Munoz-Almagro C Ferrer P Perez M Lailla JM Identification of vaccine human papillomavirus genotypes in squamous intraepithelial lesions (CIN2-3) Gynecol Oncol 2008 111 1 9 12 10.1016/j.ygyno.2008.06.012 18684497 · DOI · Paper page
  60. [64]Sjoeborg KD Trope A Lie AK Jonassen CM Steinbakk M Hansen M HPV genotype distribution according to severity of cervical neoplasia Gynecol Oncol 2010 118 1 29 34 10.1016/j.ygyno.2010.03.007 20406711 · DOI · Paper page
  61. [65]Wright TC Jr Stoler MH Behrens CM Apple R Derion T Wright TL The ATHENA human papillomavirus study: design, methods, and baseline results Am J Obstet Gynecol 2012 206 1 46 e1 e11 10.1016/j.ajog.2011.07.024 21944226 · DOI
  62. [66]Halfon P Lindemann ML Raimondo A Ravet S Camus C Khiri H HPV genotype distribution according to severity of cervical neoplasia using the Digene HPV genotyping LQ test Arch Virol 2013 158 6 1143 9.68 10.1007/s00705-012-1584-4 23299934 PMC3668127 · DOI
  63. [67]Wheeler CM Hunt WC Cuzick J Langsfeld E Pearse A Montoya GD A population-based study of human papillomavirus genotype prevalence in the United States: baseline measures prior to mass human papillomavirus vaccination Int J Cancer 2013 132 1 198 207 10.1002/ijc.27608 22532127 PMC3852415 · DOI
  64. [68]Chatterjee A The next generation of HPV vaccines: nonavalent vaccine V503 on the horizon Expert Rev Vaccines 2014 13 11 1279 90 10.1586/14760584.2014.963561 25256262 · DOI
  65. [69]Malagon T Drolet M Boily MC Franco EL Jit M Brisson J Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis Lancet Infect Dis 2012 12 10 781 9 10.1016/S1473-3099(12)70187-1 22920953 · DOI
  66. [70]Halec G Alemany L Lloveras B Schmitt M Alejo M Bosch FX Pathogenic role of the eight probably/possibly carcinogenic HPV types 26, 53, 66, 67, 68, 70, 73 and 82 in cervical cancer J Pathol 2014 234 4 441 51 10.1002/path.4405 25043390 · DOI

Cited by

Sorted by citations

Authors
Martins, T. R., Mendes de Oliveira, C., Rosa, L. R., de Campos Centrone, C., Rodrigues, C. L. R., Villa, L. L., & Levi, J. E.
Affiliations
Universidade de São Paulo (BR)
Corresponding author
Martins, Toni Ricardo
ORCID
Venue
Virology Journal
Publisher
Springer Science and Business Media LLC
Published
2016-08-12
Volume
13
Issue
1
Pages
138-138
ISSN
1743-422X (ISSN-L)
DOI
10.1186/s12985-016-0594-3
PMC
PMC4982268
OpenAlex
W2518081258
Cited by
42
References
1
Citations by year
2026: 1 · 2025: 3 · 2024: 4 · 2023: 5 · 2022: 3 · 2021: 10 · 2020: 6 · 2019: 3 · 2018: 4 · 2017: 3
FWCI
3.13
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Virology Journal (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (publishedVersion)
Funders
  • CNPq (573799/2008-3)
  • FAPESP (2008/57889-1)
Topics
  • Health Sciences › Medicine › Epidemiology › Cervical Cancer and HPV Research
  • Life Sciences › Immunology and Microbiology › Microbiology › Reproductive tract infections research
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Women's cancer prevention and management
Keywords
human papillomavirus, HPV genotype distribution, high-risk HPV, low-risk HPV, cervical lesions, cervical cytology, HPV16, HPV 56, Hybrid Capture 2, cobas HPV test, ASCUS, low-grade squamous intraepithelial lesion, high-grade squamous intraepithelial lesion
MeSH terms
Adolescent, Adult, Aged, Aged, 80 and over, Brazil, Uterine Cervical Neoplasms, Female, Genotype, Humans, Middle Aged, Vaginal Smears, Papillomaviridae, Papillomavirus Infections, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review